RBPJ
Recombining binding protein suppressor of hairless
Also known as: CBF1, IGKJRB, IGKJRB1, KBF2, RBP-J, RBPJK, RBPSUH, SUH, SUH_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q06330
- Gene
- RBPJ
- Ensembl
- ENSG00000168214
- Chromosome
- 4
- Canonical length
- 500 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
The protein encoded by this gene is a transcriptional regulator important in the Notch signaling pathway. The encoded protein acts as a repressor when not bound to Notch proteins and an activator when bound to Notch proteins. It is thought to function by recruiting chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins to Notch signaling pathway genes. Several transcript variants encoding different isoforms have been found for this gene, and several pseudogenes of this gene exist on chromosome 9. [provided by RefSeq, Oct 2013]
Canonical amino-acid sequenceUniProt
500 residues, UniProt reviewed canonical sequence.
>Q06330|RBPJ
1 MDHTEGSPAE EPPAHAPSPG KFGERPPPKR LTREAMRNYL KERGDQTVLI LHAKVAQKSY
61 GNEKRFFCPP PCVYLMGSGW KKKKEQMERD GCSEQESQPC AFIGIGNSDQ EMQQLNLEGK
121 NYCTAKTLYI SDSDKRKHFM LSVKMFYGNS DDIGVFLSKR IKVISKPSKK KQSLKNADLC
181 IASGTKVALF NRLRSQTVST RYLHVEGGNF HASSQQWGAF FIHLLDDDES EGEEFTVRDG
241 YIHYGQTVKL VCSVTGMALP RLIIRKVDKQ TALLDADDPV SQLHKCAFYL KDTERMYLCL
301 SQERIIQFQA TPCPKEPNKE MINDGASWTI ISTDKAEYTF YEGMGPVLAP VTPVPVVESL
361 QLNGGGDVAM LELTGQNFTP NLRVWFGDVE AETMYRCGES MLCVVPDISA FREGWRWVRQ
421 PVQVPVTLVR NDGIIYSTSL TFTYTPEPGP RPHCSAAGAI LRANSSQVPP NESNTNSEGS
481 YTNASTNSTS VTSSTATVVSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RBPJ can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 52 nTPM
Expression across tissuesHPA
Tissue
- placenta: 52 nTPM
- bone marrow: 48 nTPM
- adipose tissue: 38 nTPM
- smooth muscle: 36 nTPM
- endometrium: 34 nTPM
- spinal cord: 33 nTPM
Single-cell type
- hofbauer cells: 4,704 nCPM
- macrophages: 1,463 nCPM
- neutrophils: 1,204 nCPM
- cdc: 732 nCPM
- neutrophil progenitors: 657 nCPM
- oligodendrocytes: 540 nCPM
Immune cell
- neutrophil: 222 nTPM
- myeloid DC: 136 nTPM
- eosinophil: 113 nTPM
- classical monocyte: 95 nTPM
- intermediate monocyte: 78 nTPM
- non-classical monocyte: 78 nTPM
Brain region
- white matter: 116 nTPM
- basal ganglia: 91 nTPM
- medulla oblongata: 89 nTPM
- pons: 84 nTPM
- midbrain: 83 nTPM
- hypothalamus: 80 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RBPJ.
Disease | AllUniProt
Conditions RBPJ is implicated in, by any mechanism.
- Adams-Oliver syndrome 3 (AOS3) MIM:614814
Disease | GeneticClinVar
7 pathogenic / likely-pathogenic of 231 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Adams-Oliver syndrome 3
- Inborn genetic diseases
- Type 2 diabetes mellitus
Disease | ImmuneIEDB
Conditions an epitope on RBPJ was assayed in.
ReferencesPubMed · IEDB
Publications for RBPJ from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis.
2013 · Neurology · RCR 0.8 · 27 citations - Enhanced expression and autoimmunity of recombination signal binding protein-jkappa in human dilated cardiomyopathy.
1999 · Biochem Biophys Res Commun · RCR 0 · 2 citations - Autoantibody reactome analysis reveals novel biomarkers for idiopathic retroperitoneal fibrosis.
2026 · Rheumatology (Oxford)
Reference: T cellIEDB
1 publication
- Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.
2017 · Clin Cancer Res · RCR 0.8 · 29 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.24
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.57
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiogenesis
- aortic valve development
- atrioventricular canal development
- auditory receptor cell fate commitment
- B cell differentiation
- blood vessel lumenization
- blood vessel remodeling
- cardiac left ventricle morphogenesis
- cardiac muscle cell fate commitment
- cardiac muscle cell myoblast differentiation
- club cell differentiation
- defense response to bacterium
- dorsal aorta morphogenesis
- endocardium morphogenesis
- epidermal cell fate specification
- epithelial cell proliferation
- epithelial to mesenchymal transition
- epithelial to mesenchymal transition involved in endocardial cushion formation
- hair follicle maturation
- heart development
- humoral immune response
- inflammatory response to antigenic stimulus
- keratinocyte differentiation
- labyrinthine layer blood vessel development
- myeloid dendritic cell differentiation
- negative regulation of cell differentiation
- negative regulation of cold-induced thermogenesis
- negative regulation of DNA-templated transcription
- negative regulation of ossification
- negative regulation of stem cell proliferation
- negative regulation of transcription by RNA polymerase II
- Notch signaling pathway
- outflow tract morphogenesis
- pituitary gland development
- positive regulation of BMP signaling pathway
- positive regulation of canonical Wnt signaling pathway
- positive regulation of cardiac muscle cell proliferation
- positive regulation of cell proliferation involved in heart morphogenesis
- positive regulation of epithelial cell proliferation
- positive regulation of gene expression
- positive regulation of transcription by RNA polymerase II
- positive regulation of transcription of Notch receptor target
- pulmonary valve development
- regulation of cell adhesion involved in heart morphogenesis
- regulation of generation of precursor metabolites and energy
- regulation of timing of cell differentiation
- regulation of transcription by RNA polymerase II
- sebaceous gland development
- secondary heart field specification
- somatic stem cell population maintenance
- somitogenesis
- stem cell proliferation
- ventricular septum morphogenesis
- ventricular trabecula myocardium morphogenesis
- arterial endothelial cell fate commitment
- blood vessel endothelial cell fate specification
- positive regulation of ephrin receptor signaling pathway
- positive regulation of ERBB signaling pathway
Molecular functions
- chromatin binding
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription factor binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II-specific DNA-binding transcription factor binding
- sequence-specific DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- p53-like transcription factor, DNA-binding domain superfamily
- Immunoglobulin-like fold
- Immunoglobulin E-set
- Beta-trefoil DNA-binding domain
- RBP-J/Cbf11/Cbf12, DNA binding
- Beta-trefoil domain superfamily
- RBP-J/Cbf11, DNA binding domain superfamily
- RBP-Jkappa, IPT domain
- Suppressor of hairless-like
- Beta-trefoil DNA-binding domain
- LAG1, DNA binding
- TIG domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RBPJ in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RBPJ as an antibody target. Whether an autoantibody or antibody against RBPJ could matter depends on whether native RBPJ is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RBPJ is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RBPJ as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...